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background
 
Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis.
 
methods
 
We conducted a double-blind, randomized, placebo-controlled multicenter study that
assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg
three times daily) added to standard therapy with prednisone plus azathioprine. The
primary end points were changes between baseline and month 12 in vital capacity and
in single-breath carbon monoxide diffusing capacity (D
 
l
 
co
 
).
 
results
 
A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and
90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo)
had usual interstitial pneumonia, as confirmed by high-resolution computed tomog-
raphy and histologic findings reviewed by expert committees, and did not withdraw
consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcys-
teine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one
year of treatment. Acetylcysteine slowed the deterioration of vital capacity and D
 
l
 
co
 
:
at 12 months, the absolute differences in the change from baseline between patients
taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence
interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02),
and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to
1.23), or 24 percent, for D
 
l
 
co
 
 (P=0.003). Mortality during the study was 9 percent
among patients taking acetylcysteine and 11 percent among those taking placebo
(P=0.69). There were no significant differences in the type or severity of adverse events
between patients taking acetylcysteine and those taking placebo, except for a signifi-
cantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03).
 
conclusions
 
Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone
and azathioprine, preserves vital capacity and D
 
l
 
co
 
 in patients with idiopathic pulmo-
nary fibrosis better than does standard therapy alone.
abstract
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diopathic pulmonary fibrosis is a
 
chronic progressive interstitial pneumonia
with a poor prognosis.
 
1-4 
 
It has been proposed
that a pathogenetic mechanism of idiopathic pul-
monary fibrosis is repeated lung injury, with aber-
rant progressive fibrotic reaction.
 
5-9
 
 If this is the
case, it may explain why treatment with corticoste-
roids and immunosuppressive agents results in only
slight therapeutic benefit.
 
3,10-12
 
An oxidant–antioxidant imbalance may contrib-
ute to the disease process in idiopathic pulmonary
fibrosis.
 
13-20
 
 Acetylcysteine, a precursor of the ma-
jor antioxidant glutathione, given at a daily dose of
1800 mg, has been shown to restore depleted pul-
monary glutathione levels
 
16-19 
 
and to result in a
statistically significant improvement in lung func-
tion in patients with fibrosing alveolitis after 12
weeks
 
18
 
 of treatment.
We conducted the IFIGENIA (Idiopathic Pulmo-
nary Fibrosis International Group Exploring 
 
N
 
-Ace-
tylcysteine I Annual) trial to test the hypothesis that
a high dose of acetylcysteine, administered over a
period of one year in addition to prednisone and
azathioprine, would slow the functional deteriora-
tion in patients with idiopathic pulmonary fibrosis.
 
21
 
study design
 
This study was a multinational, double-blind, ran-
domized, placebo-controlled, parallel-group trial.
The study treatment consisted of oral administra-
tion of 
 
N
 
-acetylcysteine (Fluimucil, Zambon Group)
in 600-mg effervescent tablets three times daily or
matched placebo. In addition, the patients were
given prednisone (starting dose, 0.5 mg per kilo-
gram of body weight per day; 0.4 mg per kilogram
per day at month 2; and 0.3 mg per kilogram per
day at month 3; the dose was progressively reduced
to 10 mg per day in months 4, 5, and 6, and this
dose was maintained until month 12) and azathi-
oprine (2 mg per kilogram per day), in addition to
the usual care, as recommended by the American
Thoracic Society/European Respiratory Society In-
ternational Consensus.
 
21,22
 
inclusion and exclusion criteria
 
Patients 18 through 75 years of age with a histolog-
ic or radiologic pattern typical of usual interstitial
pneumonia
 
21-27
 
 were included after other causes
of usual interstitial pneumonia had been ruled out.
The inclusion criteria were as follows. A high-reso-
lution computed tomographic (CT) scan was very
suggestive or consistent with a probable diagnosis
of usual interstitial pneumonia.
 
21-25
 
 In patients
younger than 50 years, open or thoracoscopic lung
biopsy was mandatory and showed a pattern of
usual interstitial pneumonia
 
21,22,26,27
 
; lung biopsy
was optional for older patients. In the absence of
lung biopsy, a transbronchial biopsy was strongly
advocated to exclude alternative diagnoses. Bron-
choalveolar lavage must have been performed at
any time before inclusion and must have failed to
show features supporting alternative diagnoses.
The duration of the disease was more than three
months, and bibasilar inspiratory crackles were
present. In addition, the following functional ab-
normalities were present: a dyspnea score of at
least 2 on a scale of 0 (minimum) to 20 (maxi-
mum),
 
28
 
 vital capacity of no more than 80 percent
of the predicted value or total lung capacity less
than 90 percent of the predicted value, and single-
breath carbon monoxide diffusing capacity (D
 
l
 
co
 
)
less than 80 percent of the predicted value.
 
29,30
 
Patients were excluded if the standard regimen
with prednisone and azathioprine was contraindi-
cated or not justified for them or if they presented
with a known intolerance to acetylcysteine. Further
exclusion criteria were treatment with prednisone
at a dose of at least 0.5 mg per kilogram per day or
with azathioprine at a dose of at least 2 mg per kilo-
gram per day during the month before inclusion in
the study, or treatment with acetylcysteine at a dose
of more than 600 mg per day for more than three
months in the previous three years. Other reasons
for exclusion were concomitant or preexisting dis-
eases, abnormalities, or treatment at study entry or
in the past with drugs (such as antioxidants and
antifibrotic drugs) that interfere with the diagnosis,
severity, therapy, or prognosis of idiopathic pulmo-
nary fibrosis.
 
determination of sample size
 
The sample size was calculated to provide a power
of 80 percent (
 
a
 
=0.05 by two-sided test) to detect a
treatment difference between the two groups of 15
percent for vital capacity and 20 percent for D
 
l
 
co
 
after one year. On the basis of previous data
 
18,31
 
and with an expected withdrawal rate of 25 percent,
including patients who died, a total of 150 patients
with confirmed idiopathic pulmonary fibrosis were
to be enrolled.
i
methods
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radiologic and histologic committees
 
Independent committees of radiologic and histo-
logic experts, who were blinded to the patients’
baseline data, confirmed or rejected each diagnosis
on the basis of published criteria
 
21-27 
 
for the diag-
nosis of usual interstitial pneumonia by high-reso-
lution CT and surgical lung biopsy, respectively. The
committees either confirmed the diagnosis with a
“yes” (very suggestive or probable diagnosis) or re-
jected it with a “no” (diagnosis unlikely). In addi-
tion, the severity scores according to high-resolu-
tion CT were assessed,
 
23,24 
 
and chest radiographic
scores were estimated for the clinical, radiologic,
and physiological (CRP) score.
 
28
 
primary and secondary end points
 
The primary end points were the absolute changes
in vital capacity and D
 
l
 
co
 
 between baseline and
month 12, measured according to the European
Respiratory Society guidelines.
 
29,30
 
 Post hoc, we
evaluated changes in vital capacity of more than 10
percent or 0.2 liter and changes in D
 
l
 
co
 
 of more
than 15 percent or 1 mmol per minute per kilopas-
cal as categorical variables, because these were re-
cently shown to be related to the risk of death.
 
32-34
 
The following prespecified secondary end points
were assessed for changes between baseline and 12
months: vital capacity and D
 
l
 
co
 
 as percentages of
the predicted value and D
 
l
 
co
 
:alveolar volume as ab-
solute change and percentage of the predicted value;
CRP score
 
28
 
; dyspnea score
 
28
 
; maximum exercise
indexes (load [W'
 
max
 
], oxygen uptake [V'O
 
2
 
max
 
],
and ventilation [V'E
 
max
 
])
 
35
 
; scores of ground-glass
opacities and of fibrosis on high-resolution CT
 
24
 
(ranging from 0 [minimum] to 5 [maximum]);
health status according to the St. George’s Respi-
ratory Questionnaire (total scores range from 0 to
100, with higher scores indicating a worse quality
of life)
 
36
 
; number of adverse effects and withdraw-
als; and mortality during the study and up to one
month after withdrawal.
 
randomization and evaluation
 
At the screening visit, the patients were checked to
determine whether they met the inclusion or exclu-
sion criteria, potentially eligible patients were ran-
domly assigned to treatment with study medication,
and treatment was started. High-resolution CT im-
ages and histologic slides, if available, were sent to
the members of the expert committees, without any
additional patient information, and patients for
whom the diagnosis of usual interstitial pneumo-
nia was not confirmed were excluded from the
study. This process generally took four to six weeks.
Randomization of treatment (with a 1:1 ratio of
acetylcysteine to placebo) was performed centrally
with the use of a computer-generated randomiza-
tion list stratified (in blocks of four) according to
country and whether the vital capacity was 60 per-
cent or less of the predicted value or more than 60
percent of the predicted value. The patients under-
went clinical examination, laboratory tests, lung-
function tests, chest radiography, and assessment
of adverse events and drug compliance every three
months. Drug noncompliance (defined by an intake
of less than 50 percent of the study medication)
was determined by counting the returned tablets.
The findings from high-resolution CT, the maxi-
mum exercise test, and the St. George’s Respirato-
ry Questionnaire were evaluated every six months.
If standard therapy had to be adapted (for exam-
ple, because of adverse effects, poor compliance,
or clinical worsening), the patient was treated ac-
cording to the preference of each center, with the
drug-exclusion criteria, especially concerning anti-
oxidants and antifibrotic drugs, taken into consid-
eration. Continuation of treatment with acetylcys-
teine or placebo and regular follow-up visits was
recommended if it was compatible with the medi-
cal condition.
Safety was continuously monitored by central
collection of records of all serious adverse events.
All adverse events, including mortality, were re-
corded by the investigator until one month after the
patient completed or withdrew from the study. Pa-
tients were considered to have withdrawn from the
study if they discontinued the follow-up visits for
any reason.
The study was conducted according to the cur-
rent standards of Good Clinical Practice of the Inter-
national Conference on Harmonisation
 
37
 
 and na-
tional regulations. The protocol was approved by
local ethics committees. All patients gave written
informed consent and were free to withdraw at any
time. Regular monitoring and sample audits were
performed at the centers throughout the study.
The study was designed and analyzed by a com-
mittee composed of 19 academic physicians expe-
rienced in idiopathic pulmonary fibrosis, 1 inde-
pendent statistician, and 3 representatives of the
sponsor. The sponsor held the data but placed no
limitations on study design, data analysis, or the
content of the manuscript. The statistical analysis
was performed by an independent statistical com-
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pany (Innopharma, Milan). All authors participat-
ed in the preparation of the manuscript and had
full and unfettered access to the raw data and
analyses.
 
statistical analysis
 
The analyses were based on data from all patients
who underwent randomization, met the inclusion
criteria for the study, received the trial medication
 
Figure 1. Disposition of Patients.
 
For a patient to be included in the study, at least two of the three members of each committee or at least two members 
of the radiology committee (if no biopsy was available) had to confirm the diagnosis of usual interstitial pneumonia.
Consent withdrawn: 1
Death: 1
Acetylcysteine, confirmed
and included: 80
Acetylcysteine, not
included: 12
Usual interstitial 
pneumonia not 
confirmed: 10
Consent withdrawn
before start of
treatment: 2
Placebo, not included: 15
Usual interstitial 
pneumonia not 
confirmed: 12
Consent withdrawn
before start of
treatment: 3
Placebo, confirmed and
included: 75
Acetylcysteine,
available for efficacy
analysis: 80
Placebo, available
for efficacy analysis: 75
Withdrawn: 16 (20%)
Prohibited therapy: 3
Withdrawn by investi-
gator: 3
Consent withdrawn: 4
Adverse events: 2
Noncompliance: 1
Other: 3
Withdrawn: 16 (21%)
Prohibited therapy: 2
Withdrawn by investi-
gator: 2
Consent withdrawn: 4
Adverse events: 2
Noncompliance: 2
Ineffective treatment
or worsening con-
dition: 4
Death: 7 (9%)
Disease progression: 3
Respiratory tract 
infection: 3
Heart failure: 1
Death: 8 (11%)
Disease progression: 4
Respiratory tract 
infection: 1
Cardiac arrest: 1
Myocardial infarction: 1
Cancer: 1
Randomized: 182
Acetylcysteine: 92
Placebo: 90
Screened: 184
Completed study:
51 (68%)
Completed study:
57 (71%)
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at least once, and underwent at least baseline ob-
servation. Missing data were replaced by the last-
observation-carried-forward (LOCF) method for all
patients who underwent at least one lung-function
measurement after baseline.
The statistical analysis was based on a stepwise,
fixed-effects analysis of covariance (ANCOVA)
(Proc GLM; SAS, version 8.0), which included
country and treatment group in its general design
as main fixed factors, country-by-treatment as an
 
*
 
The baseline values for the primary and secondary end points are given in Tables 2 and 3. P
 
a
 
O
 
2 
 
denotes partial pressure 
of alveolar oxygen, PaO
 
2
 
 partial pressure of arterial oxygen, and SGRQ the St. George’s Respiratory Questionnaire (for 
which total scores can range from 0 to 100, with higher scores indicating a worse quality of life). Plus–minus values are 
means ±SD.The distribution of patients randomly assigned to treatment according to country was as follows: Germany: 
63 total — 33 acetylcysteine, 30 placebo; France: 41 total — 20 acetylcysteine, 21 placebo; Spain: 21 total — 10 acetyl-
cysteine, 11 placebo; Belgium: 20 total — 10 acetylcysteine, 10 placebo; the Netherlands: 19 total — 9 acetylcysteine, 
10 placebo; and Italy: 18 total — 10 acetylcysteine, 8 placebo.
† Current smokers were defined as those actively smoking, irrespective of the number of cigarettes smoked per day. 
Former smokers were defined as those who had stopped smoking at least three months previously.
 
‡ Baseline results for vital capacity were not available for two patients who were excluded from the study.
 
Table 1. Baseline Characteristics of the Study Population.*
Characteristic* Patients Included in the Study
Patients Excluded from the Study
(N=27)
 
Acetylcysteine
(N=80)
Placebo 
(N=75)
Sex — %
Male 69 75 87
Female 31 25 13
Age — yr 62±9 64±9 58±11
Smoking status — %†
Current smoker 3.8 6.7 7.7
Former smoker 57.5 62.7 61.5
Never smoked 38.8 30.7 30.8
Months since diagnosis
Mean 19.9±28.3 18.9±33.1 14.0±26.5
Median 5.0 3.0 5.5
Diagnosed within previous 6 mo — no. (%) 39 (49) 42 (56) 13 (48)
Underwent surgical lung biopsy — no. (%) 38 (48) 35 (47) 24 (89)
Vital capacity — no. of patients‡
>60% 49 53 17
≤60% 31 22 8
Total lung capacity
Volume — liters 3.72±1.00 3.72±0.94 4.11±1.37
% of predicted value 62.1±13.9 61.6±11.5 64.4±15.1
P
 
a
 
O
 
2
 
¡PaO
 
2
 
 at rest — mm Hg 31.6±13.8 30.1±11.8 28.9±13.9 
PaO
 
2
 
 at rest — mm Hg 70.1±12.7 72.0±11.2 73.8±13.7
Bronchoalveolar lavage
Fluid instilled — ml 141.4±50.9 146.6±52.8 132.7±64.8
Lymphocytes — % 10.8±11.8 10.6±9.5 19.5±22.8
Neutrophils — % 13.2±16.3 17.4±21.0 9.5±10.6
Eosinophils — % 6.1±9.6 4.3±5.5 4.3±4.8
CD4:CD8 cell ratio 1.6±1.3 2.1±2.4 1.2±0.7
Total SGRQ score 50±18 52±16 —
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interaction, and baseline values as covariates. The
following potential cofactors were assessed: smok-
ing history (current or former smokers vs. those who
had never smoked), age (<65 years vs. ≥65 years),
duration of disease since diagnosis (≤6 months vs.
>6 months), D
 
l
 
co
 
 (≤40 percent vs. >40 percent of
the predicted value), vital capacity (≤60 percent vs.
>60 percent of the predicted value), sex (male vs.
female), and whether a biopsy had been performed.
After evaluation of the assumptions underlying
the ANCOVA model, the first goal was to obtain the
model that best described the data (with treatment
excluded); the second goal was then to apply that
model to compare the effects of acetylcysteine and
placebo. To obtain the best model, we iteratively
tested all possible combinations of the cofactors,
with the aim of selecting the model in which the
smallest variability (P<0.001) and the highest R
 
2
 
value (>0.5) were reached. The relevant combina-
tions of cofactors were then included as fixed fac-
tors in the model.
To assess the robustness of the LOCF–ANCOVA
primary analysis, a likelihood-based method was
applied; this method used a mixed-effect model
and was developed under the MAR (missing at ran-
dom) framework by the MAR method.
 
38,39
 
 With
the mixed-effect approach, information from the
observed data is not explicitly imputed, and no ad-
ditional data manipulation or analysis is required
to accommodate the missing data. Two sensitivity
analyses were performed with the mixed-effect
model repeated-measure approach (MMRM) on
different data sets (but without replacing missing
data). The mixed procedure of the SAS package
was used, with treatment and time as fixed effects,
patients as random effects, and the observed values
as the response variable. The first analysis was per-
formed on the LOCF data set, which was based on
all patients with confirmed usual interstitial pneu-
monia who had been randomly assigned to treat-
ment, had taken at least one dose of the study drug,
and had undergone at least one lung-function eval-
 
* CI denotes confidence interval, LOCF the last observation carried forward, and LS least squares. Plus–minus values are means ±SD except for 
LS-LOCF, for which the mean ±SE is given.
† The nominal P value after correction for multiple tests (statistically significant at P<0.025) is given.
‡ The relative difference is the difference between the LS means for the acetylcysteine group and the placebo group, according to the following 
equation: [(LS-LOCF
 
acetylcysteine
 
¡LS-LOCF
 
placebo
 
)÷LS-LOCF
 
placebo
 
]¬100.
§ Data were not available for two patients.
 
¶LS-LOCF is the LS (or adjusted) mean from the LOCF analysis of variance.
 
Table 2. Effects of Acetylcysteine on Vital Capacity (VC) and Single-Breath Carbon Monoxide Diffusing Capacity (D
 
l
 
co
 
) at 12 Months
 
.*
 
Measurement No. of Patients
Value for Patients
Taking Acetylcysteine
Value for Patients
Taking Placebo
Absolute Difference
(95% CI)
P
Value†
Relative 
Difference‡
 
Acetylcysteine Placebo  
 
liters percent
 
VC 
 
Baseline 80 75 2.29±0.68 2.36±0.74
12 mo 55§ 51 2.31±0.79 2.26±0.72
12 mo LOCF 71 68 2.22± 0.77 2.17±0.71
Mean difference between 
baseline value and 
12 mo LOCF (95% CI)
¡0.06 (¡0.14 to 0.02) ¡0.19 (¡0.29 to ¡0.09)
LS-LOCF¶ 71 68 2.27±0.05 2.10±0.05 0.18 (0.03 to 0.32)  0.02 9
 
mmol/min/kPa
 
D
 
L
 
co
 
Baseline 79 74 3.85±1.41 3.90±1.39
12 mo 48 47 4.20±2.07 3.46±1.22
12 mo LOCF 68 63 3.74±1.99 3.20±1.26
Mean difference between 
baseline value and 
12 mo LOCF (95% CI)
¡0.11 (¡0.47 to 0.25) ¡0.70 (¡0.95 to ¡0.45)
LS-LOCF¶ 68 63 3.85±0.17 3.10±0.18 0.75 (0.27 to 1.23) 0.003 24
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uation after baseline. The second analysis was per-
formed on the baseline data set, which was the
same as the LOCF data set, except that it included
data from patients whose lung function had been
evaluated only at baseline. The two sensitivity
analyses performed to test the robustness of the
LOCF–ANCOVA analysis confirmed the results for
the primary end points.
There were no interim analyses of efficacy. All
reported P values are two-sided and were not ad-
justed for multiplicity. Because two statistical tests
were performed for the analysis of the primary end
points, the nominal P value for defining statistical
significance was reduced from P<0.05 to P<0.025.
Fisher’s exact test was used to evaluate categorical
variables, such as adverse events. All of the varia-
bles are expressed as means ±SD, unless otherwise
specified, and also as medians, quartiles, and min-
imum–maximum ranges where appropriate.
 
enrollment, patient characteristics, 
and follow-up
 
Between March 2000 and July 2002, 184 patients
were screened in 36 centers in six countries, and
182 were randomly assigned to treatment (Fig. 1).
Of these 182 patients, 155 (85 percent) were in-
cluded in the analysis. In 82 patients (53 percent),
the diagnosis was based on high-resolution CT
only; in 73 patients (47 percent), the diagnosis was
based on both high-resolution CT and histologic
findings. Twenty-seven patients were not included
in the analysis: 5 withdrew consent before starting
treatment, and 22 (12 percent) were excluded be-
cause the diagnosis of usual interstitial pneumonia
was rejected (by histologic findings in 10, by high-
resolution CT in 8, and by both diagnostic meth-
ods in 4).
results
 
Figure 2. Vital Capacity and Single-Breath Carbon Monoxide Diffusing Capacity (D
 
l
 
co
 
) at 6 and 12 Months, as Compared 
with Baseline.
 
Mean values for vital capacity (Panels A and B) and D
 
l
 
co
 
 (Panels C and D) are shown both as absolute amounts and as 
percentages of the predicted value; 
 
I
 
 bars represent SEMs. There are almost no changes in the acetylcysteine group, in 
contrast with the placebo group. The last-observation-carried-forward analysis of vital capacity was based on 71 patients 
in the acetylcysteine group (with data imputed for 16 patients) and 68 in the placebo group (with data imputed for 17 pa-
tients); the analysis of D
 
l
 
co
 
 was based on 68 patients in the acetylcysteine group (with data imputed for 20 patients) and 
63 in the placebo group (with data imputed for 16 patients).
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No significant differences in baseline character-
istics were found between the 80 patients assigned
to acetylcysteine and the 75 assigned to placebo
(Table 1). At the beginning of the study, eight pa-
tients assigned to acetylcysteine and two assigned
to placebo were receiving continuous oxygen ther-
apy. Forty-seven patients (30 percent) had been
treated with prednisone (16 patients assigned to
acetylcysteine and 13 to placebo), azathioprine
(8 assigned to acetylcysteine and 5 to placebo), or
both (2 assigned to acetylcysteine and 3 to placebo).
Of the 155 patients for whom the data were an-
alyzed, 108 (70 percent, 57 assigned to acetylcys-
teine and 51 to placebo) completed the one-year
study (Fig. 1). However, the standard therapy had
been changed for 24 of these 155 patients (15 per-
cent, 13 assigned to acetylcysteine and 11 to pla-
cebo) during the study. Three patients receiving
acetylcysteine and 11 receiving placebo started con-
tinuous oxygen therapy. Thirty-two patients (16 re-
ceiving acetylcysteine [20 percent] and 16 receiving
placebo [21 percent]) withdrew from the study, for
 
Table 3. Effects of Acetylcysteine on Secondary End Points at 12 Months.*
Measurement
Value for Patients
Taking Acetylcysteine
Value for Patients
Taking Placebo
Absolute Difference
(95% CI)
P
Value
Relative
Difference†
 
percent
 
Lung function
 
VC (% of predicted)
Baseline 64.76±15.41 66.57±14.42
12 mo 63.14±19.98 61.59±15.17
LS mean‡ 65.13±1.85 60.34±1.85 4.79 (0.80 to 8.77) 0.02 8
D
 
l
 
co
 
 (% of predicted)
Baseline 43.04±13.10 44.79±15.15
12 mo 40.85±14.85 38.75±14.75
LS mean 41.60±1.35 36.52±1.45 5.08 (1.17 to 8.99) 0.01 14
D
 
l
 
co
 
:VA (mmol/min/kPa/liter)
Baseline 1.14±0.45 1.11±0.35
12 mo 1.21±0.81 0.99±0.31
LS mean 1.19±0.81 1.00±0.31 0.19 (0.01 to 0.37) 0.04 19
D
 
l
 
co
 
:VA (% of predicted)
Baseline 72.09±24.31 72.80±20.44
12 mo 70.92±25.43 66.71±21.44
LS mean 72.09±25.43 65.49±21.44 6.60 (1.05 to 12.15) 0.02 10
 
Exercise§
 
W'
 
max
 
 (W)
Baseline 86.02±41.60 82.38±36.46
12 mo 88.76±38.53 73.61±30.86
LS mean 84.71±3.53 77.27±3.38 7.44 (¡2.34 to 17.23) 0.13 10
V'O
 
2
 
max
 
 (liters/min)
Baseline 1.20±0.40 1.31±0.46
12 mo 1.26±0.52 1.16±0.43
LS mean 1.28±0.05 1.15±0.05 0.13 (¡0.01 to 0.26) 0.08 11
V'E
 
max
 
 (liters/min)
Baseline 56.75±19.44 59.03±17.09
12 mo 60.70±19.48 57.83±15.17
LS mean 61.13±1.85 57.10±1.77 4.03 (¡1.07 to 9.26) 0.12 7
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various reasons. In addition, 15 patients (10 per-
cent) died during the study: 7 of these (9 percent)
were receiving acetylcysteine, and 8 (11 percent)
were receiving placebo (P<0.69).
 
effects on primary end points
 
The LOCF analysis included 139 patients (71 re-
ceiving acetylcysteine and 68 receiving placebo, with
data imputed for 16 and 17 patients, respectively)
for the vital capacity analysis and 131 patients (68
receiving acetylcysteine and 63 receiving placebo,
with data imputed for 20 and 16 patients, respec-
tively) for the D
 
l
 
co
 
 analysis (Table 2). There was a
slower rate of loss of vital capacity in the group re-
ceiving acetylcysteine; the absolute value of vital ca-
pacity was 0.18 liter, or 9 percent, greater (P=0.02)
and the value of D
 
l
 
co
 
 was 0.75 mmol per minute
per kilopascal, or 24 percent, greater (P=0.003) in
those receiving acetylcysteine than in those receiv-
ing placebo. The analysis of D
 
l
 
co
 
 after correction
for hemoglobin levels yielded similar results: the
value was 0.81 mmol per minute per kilopascal or
 
* CI denotes confidence interval; VC vital capacity; LS least squares; D
 
l
 
co
 
 single-breath carbon monoxide diffusing capac-
ity; VA alveolar volume; W'
 
max
 
, maximum exercise load; V'O
 
2
 
max
 
 maximum oxygen uptake; V'E
 
max
 
 maximum exercise 
ventilation; CRP clinical, radiologic, and physiological; and HRCT high-resolution computed tomography. Plus–minus 
values are means ±SD except for LS mean, for which the mean ±SE is given.
† The relative difference is the difference between the LS means for the acetylcysteine group and the placebo group, 
according to the following equation: ([LS-LOCF
 
acetylcysteine
 
¡LS-LOCFplacebo]÷LS-LOCFplacebo)¬100.
‡ The LS mean is the least-squares (or adjusted) mean from the last-observation-carried-forward (LOCF) analysis of 
variance.
§ Only 61 patients in the acetylcysteine group and 67 in the placebo group were able to perform exercise.
¶Total CRP scores range from 0 to 100, CRP scores without exercise from 0 to 70, dyspnea scores from 0 to 20, and HRCT 
scores from 0 to 5. In all cases, higher scores indicate more severe symptoms or findings.
Table 3. (Continued.)
Measurement
Value for Patients
Taking Acetylcysteine
Value for Patients
Taking Placebo
Absolute Difference
(95% CI)
P
Value
Relative
Difference†
percent
CRP score¶
CRP total
Baseline 39.73±15.01 37.06±15.88
12 mo 36.80±14.50 38.68±13.85
LS mean 37.62±1.75 39.33±1.70 ¡1.71 (¡8.72 to 5.30) 0.70 5
CRP without exercise
Baseline 32.88±9.81 31.69±9.04
12 mo 32.54±10.75 33.18±9.78
LS mean 30.91±0.84 32.50±0.87 ¡1.59 (¡4.37 to 1.19) 0.17 5
Dyspnea
Baseline 8.35±4.44 7.92±3.99
12 mo 8.96±5.53 9.12±4.88
LS mean 8.88±0.49 9.20±0.51 ¡0.32 (¡1.72 to 1.09) 0.65 4
HRCT score¶
Fibrosis
Baseline 2.03±0.70 2.05±0.64
12 mo 2.27±0.74 2.22±0.65
LS mean 2.29±0.04 2.19±0.04 0.10 (¡0.02 to 0.21) 0.09 5
Ground-glass opacities
Baseline 1.76±0.63 1.79±0.65
12 mo 1.94±0.62 1.96±0.60
LS mean 1.95±0.05 1.96±0.05 ¡0.01 (¡0.15 to 0.14) 0.95 1
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25 percent greater in patients receiving acetylcys-
teine (P=0.001). None of the combinations of co-
factors included in the fixed-effects LOCF–ANCOVA
analysis were statistically significant, and therefore
the treatment comparisons are unadjusted. The
changes in vital capacity and Dlco over the 12-
month period are illustrated in Figure 2.
post hoc analysis of categorical changes
When the vital capacity data were dichotomized so
that a change in vital capacity from baseline to 12
months of more than 10 percent or 0.2 liter versus
a smaller change was treated as a categorical varia-
ble, then the condition of 63 percent of patients re-
ceiving acetylcysteine (45 of 71) and 49 percent of
those receiving placebo (33 of 68) was considered
stable or improved, and the condition of 37 percent
of those receiving acetylcysteine (26 of 71) and 51
percent of those receiving placebo (35 of 68) was
considered to have deteriorated (P=0.22). Similarly,
when the Dlco data were dichotomized so that a
change in Dlco of more than 15 percent or 1 mmol
per minute per kilopascal from baseline to 12
months versus a smaller change was treated as a
categorical variable, the condition of 57 percent of
patients receiving acetylcysteine (39 of 68) and 49
percent of those receiving placebo (31 of 63) was
considered stable or improved, and the condition of
43 percent of those receiving acetylcysteine (29 of
68) and 51 percent of those receiving placebo (32 of
63) was considered to have deteriorated (P=0.17).
effects on secondary end points
For vital capacity and Dlco expressed as percent-
ages of the predicted values, the relative differences
between the study groups at 12 months were 8 per-
cent (P=0.02) and 14 percent (P=0.01), respective-
ly (Table 3), with values higher in the group receiv-
ing acetylcysteine. The changes in other secondary
end points did not differ significantly between the
two study groups (Table 3).
compliance and safety
More than 85 percent of the patients in both groups
took on average more than 80 percent of the pre-
scribed daily dose of the study drug. The overall in-
cidence of adverse events is presented in Table 4,
and the incidence of fatal adverse events in Figure 1.
None of the differences between the study groups
were significant except for adverse events related to
bone marrow toxicity, which occurred in 4 percent
of patients receiving acetylcysteine (3 of 80) and in
13 percent of those receiving placebo (10 of 75)
(P=0.03).
Our results show that the addition of acetylcysteine
to standard therapy with prednisone and azathio-
prine in patients with idiopathic pulmonary fibro-
sis significantly slows the rate of deterioration of
the primary pulmonary surrogate end points vital
capacity and Dlco. A relative difference of 24 per-
cent was observed for Dlco and of 9 percent for vi-
tal capacity, differences that are in agreement with
the assumed differences in the sample-size power
calculation. Although we could not establish that
the acetylcysteine-related reduction in the decline
of vital capacity and Dlco translates into a survival
benefit, our data suggest that the effects of acetyl-
cysteine on the primary end points may slow dis-
ease progression.
In our opinion, the effects of acetylcysteine on
the primary end points are of clinical relevance. It
has recently been shown that decreases in vital ca-
pacity of 10 percent or more and in Dlco of 15 per-
cent or more from baseline over a period of 6 to 12
months are associated with an increased risk of
death in patients with idiopathic pulmonary fibro-
sis.32-34 Figure 2 and Table 2 show that, in the
present study, acetylcysteine reduced the declines
in vital capacity and Dlco after one year of treat-
ment. However, the present study did not docu-
ment the finding of other studies32-34 that changes
in vital capacity and Dlco are associated with sur-
vival. Other recent studies indicated that the six-
minute walk test may be a predictor of survival as
well.41,42 Such tests were not performed in this trial.
The post hoc analysis of categorical changes in
vital capacity and Dlco did not find a significant
difference between the responses to acetylcysteine
and placebo; however, the sample-size power cal-
culation indicated that at least 200 patients with id-
iopathic pulmonary fibrosis would have had to be
enrolled to detect a statistically significant differ-
ence of 10 percent for vital capacity and 15 percent
for Dlco.
The main rationale for the present study was
based on previous findings that an oxidant–anti-
oxidant imbalance existed in idiopathic pulmonary
fibrosis,13-20 that depleted glutathione levels were
restored by high doses of acetylcysteine,16-19 and
(in a pilot study) that acetylcysteine treatment had
concomitant favorable effects on lung function.18
discussion
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The favorable effects of acetylcysteine on lung func-
tion have, indeed, been confirmed by the present
trial. It was not our aim to examine whether the
therapeutic effect of the activity of acetylcysteine is
in accordance with the current hypothesis that per-
sistent lung injury from fibrosis, and not from in-
flammation, is the primary pathogenetic mecha-
nism in idiopathic pulmonary fibrosis.6-9 On the
basis of this hypothesis, there has been particular
interest in antifibrotic drugs,7 such as pirfeni-
done,43,44 and in immune modulators, especially
interferon gamma-1b.45-47 In a recent double-blind
study, pirfenidone was shown to improve vital ca-
pacity and to prevent acute exacerbations of idio-
pathic pulmonary fibrosis.44 Interferon gamma-1b
appeared to be effective in a pilot study,45 but this
was not confirmed in subsequent studies.46,47
However, a retrospective analysis of the data of
Raghu et al.46 found that a decrease of more than
10 percent in forced vital capacity (as a percentage
* All diagnoses were based on the clinical judgment of the investigator and were blindly coded by qualified persons ac-
cording to the Medical Dictionary for Regulatory Activities.40
† Lower respiratory tract infections, pneumonia, bronchopneumonia, bronchitis, acute bronchitis, and bronchial infec-
tion are included.
‡ Exacerbated dyspnea is included.
§ Increased or abnormal aspartate aminotransferase or alanine aminotransferase and increased or abnormal g-glutamyl-
transferase are included.
¶ Gastritis is included.
¿ Rhinitis, sinusitis, and nasopharyngitis are included.
**Hyperglycemia is included.
††Anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia, decreased lymphocyte count, and decreased red-
cell count are included. Bone marrow toxic effects were significantly less frequent with acetylcysteine than with placebo 
(P=0.03).
‡‡Peripheral edema is included.
§§ Fatigue is included.
Table 4. Adverse Events Occurring in at Least 5 Percent of Patients.*
Adverse Event Acetylcysteine Group Placebo Group
No. of
Adverse Events Patients (N=80)
No. of
Adverse Events Patients (N=75)
no. (%) no. (%)
All adverse events 322 72 (90) 303 67 (89)
Respiratory tract infection† 22 20 (25) 27 24 (32)
Dyspnea‡ 16 16 (20) 21 19 (25)
Fever 17 15 (19) 10 10 (13)
Liver-function test abnormal§ 15 14 (18) 13 11 (15)
Cough 15 13 (16) 17 16 (21)
Abdominal pain¶ 12 12 (15) 7 7 (9)
Upper respiratory tract infection¿ 11 11 (14) 15 13 (17)
Blood glucose increased** 9 9 (11) 12 11 (15)
C-reactive protein increased 7 6 (8) 3 3 (4)
Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)
Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)
Back pain 6 6 (8) 6 5 (7)
Respiratory failure 5 5 (6) 1 1 (1)
Bone marrow toxic effects†† 3 3 (4) 10 10 (13)
Edema‡‡ 3 3 (4) 5 5 (7)
Headache 4 3 (4) 6 6 (8)
Asthenia§§ 3 3 (4) 5 5 (7)
Influenza-like illness 3 3 (4) 5 5 (7)
Muscle cramp 1 1 (1) 4 4 (5)
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of the predicted value) is a valid measure of disease
progression.48 If the pathogenetic mechanism in
idiopathic pulmonary fibrosis is, indeed, an aber-
rant and irreversible fibrosis, then improvement
by therapy may be improbable, and at best a slow-
ing down of disease progression may be accom-
plishable.
In this study, N-acetylcysteine was administered
in three 600-mg effervescent tablets, for a total dose
of 1800 mg per day. This is three to nine times the
usual approved dose of acetylcysteine when it is ad-
ministered as an antioxidant and mucolytic agent
in chronic obstructive pulmonary disease. The ace-
tylcysteine and placebo groups had similar overall
rates of side effects, withdrawals, and treatment
failures, a result suggesting that it was unlikely that
acetylcysteine was interfering with therapy with
prednisone plus azathioprine. There was a tenden-
cy toward a higher rate of respiratory failure in the
group receiving acetylcysteine than in that receiv-
ing placebo (6 percent vs. 1 percent, P=0.24); how-
ever, eight patients in the acetylcysteine group and
only two in the placebo group were receiving oxy-
gen continuously at the beginning of the study. Fur-
thermore, compliance with the study drugs and
with the standard therapy was generally good. The
lower incidence of adverse events related to bone
marrow toxicity in the acetylcysteine group might
have been due to the augmentation of glutathione
biosynthesis induced by acetylcysteine. In recent
publications, acetylcysteine has been shown to pro-
tect hepatocytes from azathioprine-induced toxicity
by replenishing intracellular glutathione concentra-
tions.49,50
Our trial used prednisone and azathioprine as
standard therapy for all patients, as proposed by
the International Idiopathic Pulmonary Fibrosis
Consensus Statement.21 The mortality up to one
month after completion of the study or withdrawal
from the study was rather low (9 percent in the ace-
tylcysteine group and 11 percent in the placebo
group). This result suggests that the standard ther-
apy with prednisone and azathioprine may be ben-
eficial, but controlled trials are needed to confirm
this. Because our study, unlike previous studies, in-
cluded patients with both early and late stages of
idiopathic pulmonary fibrosis, the results are more
likely to be applicable to the majority of patients
seen in daily clinical practice. To our surprise, there
was no difference in the results between newly and
previously diagnosed patients, or between those
with a baseline vital capacity of more than 60 per-
cent and those with a baseline vital capacity of 60
percent or less of the predicted value. Finally, our
study illustrates the difficulty of conducting clini-
cal trials in patients with idiopathic pulmonary
fibrosis: we required 36 sites and 27 months to en-
roll 155 patients.
Some potential limitations of the study need to
be addressed. First, the evidence supporting the
better preservation of vital capacity and Dlco in the
acetylcysteine group should be interpreted with
caution, since about 30 percent of the patients were
lost to follow-up at 12 months owing to death or
withdrawal. Second, this trial does not permit firm
conclusions regarding the effects and side effects
of treatment with prednisone plus azathioprine giv-
en that there was no placebo group for these drugs.
Third, it is unknown whether acetylcysteine would
have the same effects when given without standard
therapy. Fourth, the study was not powered or de-
signed to detect an effect on survival.
In conclusion, the results of our trial demon-
strate that acetylcysteine at a dose of 600 mg three
times daily, added to prednisone and azathioprine,
in patients with idiopathic pulmonary fibrosis pre-
serves vital capacity and Dlco better than standard
therapy alone. High-dose acetylcysteine in addi-
tion to standard therapy is, therefore, a rational
treatment option for patients with idiopathic pul-
monary fibrosis.
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